| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7a3a3bd73af47cd18d1d945a41e9916
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5f0981b00e89b7275ac0b4a5b01d2af |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00 |
| filingDate |
2011-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce215c4fb16c19befa1e7998fd915c5c |
| publicationDate |
2015-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9186320-B2 |
| titleOfInvention |
Controlled release delivery system for nasal application of neurotransmitters |
| abstract |
This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019202504-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10729646-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9962394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9801834-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596181-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10898495-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019199704-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9579280-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723911-B2 |
| priorityDate |
2006-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |